Bio tech company Immutep (ASX:IMM)
has inked a deal with Pharmaceutical giants Merck and Pfizer to collaborate on an early stage clinical trial of its treatment for cancer.
The company says the collaborate and supply agreement will evaluate Immtep's lead immunotherapy product in patients with advanced solid malignancies.
Immutep says the trial will evaluate the clinical benefits of releasing the brakes and pushing the accelerator of the body's immune system at two different positions in the cancer immunity cycle.
The agreement comes six months after the company joined forces with Merck to trial a combination of drugs to treat various cancers.
And investors like the news shares in Immutep (ASX:IMM)
are up almost 10 per cent per cent to 4 cents.